Optimi Health Corp. (NASDAQ:OPTH) Sees Large Decline in Short Interest

Optimi Health Corp. (NASDAQ:OPTHGet Free Report) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 9,806 shares, a decrease of 44.5% from the August 15th total of 17,682 shares. Based on an average trading volume of 20,884 shares, the short-interest ratio is presently 0.5 days. Approximately 0.2% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

OPTH has been the topic of a number of research reports. Zacks Research raised shares of Optimi Health to a “hold” rating in a research note on Thursday, May 28th. Weiss Ratings raised Optimi Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, Wall Street Zen raised Optimi Health to a “hold” rating in a research note on Saturday, July 25th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Read Our Latest Stock Report on OPTH

Optimi Health Stock Down 3.4%

Shares of OPTH stock traded down $0.17 during trading on Wednesday, hitting $4.90. 59,730 shares of the stock traded hands, compared to its average volume of 54,365. Optimi Health has a 52-week low of $4.00 and a 52-week high of $6.40. The firm’s fifty day moving average price is $4.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.03 and a current ratio of 0.06.

Optimi Health Company Profile

(Get Free Report)

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. Optimi Health Corp. is based in VANCOUVER, BC.

Featured Stories

Receive News & Ratings for Optimi Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Optimi Health and related companies with MarketBeat.com's FREE daily email newsletter.